Serum Adenosine Deaminase Levels and Human Papillomavirus as Prognostic and Predictive Factors for Laryngeal and Pharyngeal Carcinomas

  • C. Chandrakiran
  • Thanu JogyEmail author
  • Sanjay B. Patil
Original Article


Head and neck cancer is one of the most common cancers in the world, accounting for up to 30–40% malignancies in India. Research is always on the lookout for parameters that help in early diagnosis of such disease and to explore the possibility of discovering such parameters that would assist in management of the disease by its potential to predict and prognosticate the disease. To estimate serum ADA levels and to correlate with response to therapy and also to correlate between different clinical stages and serum ADA levels and to correlate HPV status to response to therapy. A prospective cohort study. 30 patients who were diagnosed with squamous cell carcinoma of the oropharynx, hypopharynx and larynx were considered in this study. The pre and post treatment values of serum ADA was estimated in these patients and the tumour was assessed for HPV status. The difference in the in the serum ADA levels before and after treatment was 9.982 which was statistically significant with a p value of < 0.001. HPV positive status and response to therapy in the form of recurrence shows a p value of 0.485 which is not statistically significant. Serum ADA level can be used as a parameter to assess the severity of the disease and the response to treatment in cases of carcinoma of the oropharynx, hypopharynx and larynx. HPV status of the disease has its limitation in prediction and prognosis of the disease.


Squamous cell carcinoma Oropharynx Hypopharynx Larynx Serum ADA HPV 



We sincerely thank all the individuals who have supported us for the study. We thank Mr. Pradeep B K (Biocon) for scientific assistance.


  1. 1.
    Kelgandre DC et al (2016) Adenosine deaminase—a novel diagnostic and prognostic biomarker for oral SCC. Asian Pac J Cancer Prev 17(4):1865–1868CrossRefGoogle Scholar
  2. 2.
    Kapil U, Singh P, Bahadur S, Dwivedi SN, Singh R, Shukla N (2005) Assement of risk factors in laryngeal cancer in India: a case control study. Asia Pac J Cancer Prev 6(2):202–207Google Scholar
  3. 3.
    Ayude D, Gacio G, Páez de la Cadena M, Pallas E, Martínez-Zorzano VS, de Carlos A et al (2003) Combined use of established and novel tumour markers in the diagnosis of head and neck squamous cell carcinoma. Oncol Rep 10(5):1345–1350PubMedGoogle Scholar
  4. 4.
    Bansal SK, Singh RP, Narang RK, Joshi LD, Bansal AB, Agrawal AK (1991) Serum ADA activity in pulmonary tuberculosis, malignancy and non tubercular respiratory diseases. Indian J Chest Dis Allied Sci 33(4):189–193PubMedGoogle Scholar
  5. 5.
    Satyanarayan U (2001) Biochemistry. Calcutta Books and Allied (P) Ltd., CalcuttaGoogle Scholar
  6. 6.
    Hovi T, Smyth JF, Allison AC, Williams SC (1976) Role of ADA in lymphocyte proliferation. Clin Exp Immunol 1276:395–403Google Scholar
  7. 7.
    Moriwaki Y, Yamamoto T, Higashino K (1999) Enzymes involved in purine metabolism—a review of histochemical localization and functional implications. Histol Histopathol 14(4):1321–1340PubMedGoogle Scholar
  8. 8.
    Orban C, ILker D, Cetin R et al (1996) Activities of adenosine deaminase, 5′-nucleotidase, guanase and cytidine deaminase enzymes in cancerous and noncancerous human breast tissues. Breast Cancer Res Treat 37:189–193CrossRefGoogle Scholar
  9. 9.
    Raczynska J, Jonas S, Krawczinski J (1996) Diagnostic value of adenosine in some liver diseases. Clin Chem Act 13:151–154CrossRefGoogle Scholar
  10. 10.
    Ten Kate J, Van den Ingh HF, Khan PM, Bosman FT (1986) Adenosine deaminase complexing protein (ADCP) immunreactivity in colorectal adenocarcinoma. Int J Cancer 37:479–485CrossRefGoogle Scholar
  11. 11.
    Delacour H, Sauvanot C et al (2010) Analytical performances of the diazyme ADA assay on the Cobas 6000 system. Clin Biochem 43(18):1468–1471CrossRefGoogle Scholar
  12. 12.
    David GP, Sharon S, David M (eds) et al (2015) National comprehensive cancer network (NCCN) Guidelines version 1.2015 head and neck cancersGoogle Scholar
  13. 13.
    Rosner B (2000) Fundamentals of biostatistics, 5th edn. Duxbury, pp 80–240Google Scholar
  14. 14.
    Jordan RC, Lingen MW, Perez-Ordonez B et al (2012) Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 36(7):945–954CrossRefGoogle Scholar
  15. 15.
    Best SR, Niparko KJ, Pai SI (2012) Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers. Otolaryngol Clin N Am 45(4):807–822CrossRefGoogle Scholar
  16. 16.
    Schache AG, Liloglou T, Risk JM et al (2011) Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res 17(19):6262–6271CrossRefGoogle Scholar
  17. 17.
  18. 18.
    Westra WH (2009) The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol 3(1):78–81CrossRefGoogle Scholar
  19. 19.
    Ashok KJ, Pinto GJO, Kavitha AK, Palathra MJ (2008) The diagnostic and prognostic value of serum adenosine deaminase levels in head and neck cancer. J Clin Diagn Res 3:833–837Google Scholar
  20. 20.
    Sharma S, Desai PB, Metgudmath RB (2013) Evaluation of serum adenosine deaminase and retinol in patients with laryngeal cancer. Indian J Pharm Biol Res 1(4):30–34CrossRefGoogle Scholar
  21. 21.
    Mishra R, Agarwal MK, Chansuria JPN (2000) Serum adenosine deaminase levels as an index of tumor growth in head and neck malignancy. Indian J Otolaryngol Head Neck Surg 52:360–363PubMedPubMedCentralGoogle Scholar
  22. 22.
    Metgudmath RB, Sharma S, Desai PB (2013) Role of purine metabolic enzymes and vitamin A in patients with oral cancer. Int J Pharm Biol Chem Sci 2:31–37Google Scholar
  23. 23.
    Lal H, Munjal SK, Wig U, Saini AS (1987) Serum enzymes in head and neck cancer III. J Laryngol Otol 101(10):1062–1065CrossRefGoogle Scholar
  24. 24.
    Carole F, William H, Sigui L et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269CrossRefGoogle Scholar
  25. 25.
    Maura L, Wayne M, Randolph B et al (2000) Evidence for a casual association between human papillomavirus and a subset of head and neck cancer. J Natl Cancer Inst 92:709–720CrossRefGoogle Scholar
  26. 26.
    Benjamin P, Nathan C, Tamara O (1997) Human papilloma virus in head and neck cancer—an association of HPV 16 with squamous cell carcinoma of Waldeyer’s Tonsillar Ring. Cancer 79:595–604CrossRefGoogle Scholar
  27. 27.
    Maura L, Gypsyamber D, William W et al (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100:407–420CrossRefGoogle Scholar
  28. 28.
    Elaine M, Justine M, Kurt F et al (2004) Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 96:449–455CrossRefGoogle Scholar

Copyright information

© Association of Otolaryngologists of India 2018

Authors and Affiliations

  1. 1.Department of ENTM.S. Ramaiah Medical CollegeBangaloreIndia

Personalised recommendations